Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
300 IR grass pollen SLIT tablets for grass pollen rhinoconjunctivitis
2006-003258-98Phase 3Completed
- Sponsor
- Stallergenes Greer
- Start
- Aug 2006
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Oralair in allergic rhinitis (AR) and allergic rhinoconjunctivitis (ARC) (3 arms), sponsored by Stallergenes Greer. Primary endpoints: Average Adjusted Symptom Score during third pollen period, Average Adjusted Symptom Score during fourth pollen period and 1 more. Started Aug 2006; status: completed.
02
Drugs
Oralair
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2006-003258-98.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003258-98.